The nonbiologic DMARD leflunomide was approved for use in the treatment of rheumatoid arthritis in 1998. After being in use for more than a decade, which has also seen the introduction of highly effective biologic agents, a review of the benefits and risks of leflunomide therapy sheds light on the role of this drug in the treatment arsenal.
